Lymphoma

CAR-T Therapy Kymriah Approved for Relapsed/Refractory Large B-Cell Lymphoma

By May 02, 2018

Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence.

Adcetris + Chemo OK'd as Frontline Tx for Advanced Classical Hodgkin Lymphoma

By March 20, 2018

FDA approval was based on positive results from the Phase 3 ECHELON-1 trial.